Do analysts prefer SHPH or CMMB?

Chemomab Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,472.33%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than Shuttle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, SHPH or CMMB?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A

Is SHPH or CMMB more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% Chemomab Therapeutics N/A -89.03% -79.68%

Do analysts rate SHPH or PHXM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, SHPH or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is SHPH or PHXM more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% PHAXIAM Therapeutics N/A N/A N/A

Do analysts rate SHPH or MTEX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SHPH or BCDA?

BioCardia has a consensus target price of $25.00, suggesting a potential upside of 1,983.33%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Shuttle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, SHPH or BCDA?

BioCardia is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A BioCardia N/A N/A -$8.23M -$0.91 N/A

Is SHPH or BCDA more profitable?

Shuttle Pharmaceuticals' return on equity of -408.34% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% BioCardia N/A -5,456.14% -232.75%

Does the media favor SHPH or BCDA?

In the previous week, BioCardia had 2 more articles in the media than Shuttle Pharmaceuticals. MarketBeat recorded 7 mentions for BioCardia and 5 mentions for Shuttle Pharmaceuticals. BioCardia's average media sentiment score of 1.26 beat Shuttle Pharmaceuticals' score of 0.76 indicating that BioCardia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shuttle Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCardia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SHPH or BON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, SHPH or BON?

Bon Natural Life has higher revenue and earnings than Shuttle Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A Bon Natural Life $18.67M 0.49 -$2M N/A N/A

Is SHPH or BON more profitable?

Bon Natural Life's return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% Bon Natural Life N/A N/A N/A

Shuttle Pharmaceuticals (SHPH) Competitors

$4.02 +0.24 (+6.35%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$3.53 -0.49 (-12.19%)

As of 06/26/2026 07:59 PM Eastern

Compare

SHPH vs. CMMB, PHXM, MTEX, BCDA, and BON

Should you buy Shuttle Pharmaceuticals stock or one of its competitors? MarketBeat compares Shuttle Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shuttle Pharmaceuticals include Chemomab Therapeutics (CMMB), PHAXIAM Therapeutics (PHXM), Mannatech (MTEX), BioCardia (BCDA), and Bon Natural Life (BON). These companies are all part of the "pharmaceutical products" industry.

How does Shuttle Pharmaceuticals compare to Chemomab Therapeutics?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Shuttle Pharmaceuticals had 3 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 5 mentions for Shuttle Pharmaceuticals and 2 mentions for Chemomab Therapeutics. Shuttle Pharmaceuticals' average media sentiment score of 0.76 beat Chemomab Therapeutics' score of 0.43 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Positive
Chemomab Therapeutics	Neutral

Shuttle Pharmaceuticals has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Chemomab Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,472.33%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics' return on equity of -89.03% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Summary

Chemomab Therapeutics beats Shuttle Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to PHAXIAM Therapeutics?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Shuttle Pharmaceuticals has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

In the previous week, Shuttle Pharmaceuticals had 5 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 5 mentions for Shuttle Pharmaceuticals and 0 mentions for PHAXIAM Therapeutics. Shuttle Pharmaceuticals' average media sentiment score of 0.76 beat PHAXIAM Therapeutics' score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Positive
PHAXIAM Therapeutics	Neutral

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PHAXIAM Therapeutics' return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
PHAXIAM Therapeutics	N/A	N/A	N/A

Summary

Shuttle Pharmaceuticals beats PHAXIAM Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Mannatech?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, Shuttle Pharmaceuticals had 4 more articles in the media than Mannatech. MarketBeat recorded 5 mentions for Shuttle Pharmaceuticals and 1 mentions for Mannatech. Mannatech's average media sentiment score of 1.89 beat Shuttle Pharmaceuticals' score of 0.76 indicating that Mannatech is being referred to more favorably in the news media.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Positive
Mannatech	Very Positive

Shuttle Pharmaceuticals has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Comparatively, 41.5% of Mannatech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Shuttle Pharmaceuticals has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Shuttle Pharmaceuticals' return on equity of -408.34% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Mannatech	-11.97%	-2,383.34%	-40.24%

Shuttle Pharmaceuticals has higher earnings, but lower revenue than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
Mannatech	$108.04M	0.09	-$15.21M	-$6.71	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mannatech beats Shuttle Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to BioCardia?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Shuttle Pharmaceuticals' return on equity of -408.34% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
BioCardia	N/A	-5,456.14%	-232.75%

BioCardia has a consensus target price of $25.00, suggesting a potential upside of 1,983.33%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Comparatively, 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Shuttle Pharmaceuticals has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

BioCardia is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
BioCardia	N/A	N/A	-$8.23M	-$0.91	N/A

In the previous week, BioCardia had 2 more articles in the media than Shuttle Pharmaceuticals. MarketBeat recorded 7 mentions for BioCardia and 5 mentions for Shuttle Pharmaceuticals. BioCardia's average media sentiment score of 1.26 beat Shuttle Pharmaceuticals' score of 0.76 indicating that BioCardia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shuttle Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioCardia beats Shuttle Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Bon Natural Life?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bon Natural Life has higher revenue and earnings than Shuttle Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
Bon Natural Life	$18.67M	0.49	-$2M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bon Natural Life's return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Bon Natural Life	N/A	N/A	N/A

Shuttle Pharmaceuticals has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

In the previous week, Shuttle Pharmaceuticals had 4 more articles in the media than Bon Natural Life. MarketBeat recorded 5 mentions for Shuttle Pharmaceuticals and 1 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.91 beat Shuttle Pharmaceuticals' score of 0.76 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Positive
Bon Natural Life	Very Positive

Summary

Bon Natural Life beats Shuttle Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Shuttle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SHPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SHPH vs. The Competition

Export

Metric	Shuttle Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.56M	$3.01B	$6.70B	$12.22B
Dividend Yield	N/A	1.77%	2.67%	6.13%
P/E Ratio	-0.08	19.54	25.82	24.18
Price / Sales	N/A	458.80	576.05	114.38
Price / Cash	N/A	56.66	46.99	54.37
Price / Book	0.36	4.21	10.77	6.36
Net Income	-$11.72M	$64.45M	$3.58B	$337.99M
7 Day Performance	16.18%	2.22%	2.20%	0.10%
1 Month Performance	-22.66%	1.36%	1.11%	-0.11%
1 Year Performance	-88.28%	29.73%	34.26%	27.60%

Shuttle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SHPH Shuttle Pharmaceuticals	0.7976 of 5 stars	$4.02 +6.3%	N/A	-88.1%	$2.56M	N/A	N/A	5	News Coverage Short Interest Decrease High Trading Volume
CMMB Chemomab Therapeutics	2.3823 of 5 stars	$1.54 -6.0%	$25.00 +1,522.3%	-66.7%	$11.16M	N/A	N/A	20	Short Interest Increase
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
MTEX Mannatech	1.7576 of 5 stars	$5.29 -2.6%	N/A	-46.3%	$10.21M	$106.39M	N/A	250	Positive News Gap Up
BCDA BioCardia	4.2682 of 5 stars	$0.90 +3.9%	$25.00 +2,674.7%	-46.2%	$10.18M	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SHPH) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shuttle Pharmaceuticals (SHPH) Competitors

SHPH vs. CMMB, PHXM, MTEX, BCDA, and BON

How does Shuttle Pharmaceuticals compare to Chemomab Therapeutics?

Summary

How does Shuttle Pharmaceuticals compare to PHAXIAM Therapeutics?

Summary

How does Shuttle Pharmaceuticals compare to Mannatech?

Summary

How does Shuttle Pharmaceuticals compare to BioCardia?

Summary

How does Shuttle Pharmaceuticals compare to Bon Natural Life?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHPH vs. The Competition

Shuttle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shuttle Pharmaceuticals (SHPH) Competitors

SHPH vs. CMMB, PHXM, MTEX, BCDA, and BON

How does Shuttle Pharmaceuticals compare to Chemomab Therapeutics?

Does the media prefer SHPH or CMMB?

Which has more risk & volatility, SHPH or CMMB?

Do insiders & institutionals hold more shares of SHPH or CMMB?

Do analysts prefer SHPH or CMMB?

Is SHPH or CMMB more profitable?

Which has preferable valuation & earnings, SHPH or CMMB?

Summary

How does Shuttle Pharmaceuticals compare to PHAXIAM Therapeutics?

Which has stronger earnings and valuation, SHPH or PHXM?

Which has more volatility & risk, SHPH or PHXM?

Does the media prefer SHPH or PHXM?

Do institutionals & insiders believe in SHPH or PHXM?

Do analysts rate SHPH or PHXM?

Is SHPH or PHXM more profitable?

Summary

How does Shuttle Pharmaceuticals compare to Mannatech?

Does the media prefer SHPH or MTEX?

Which has more volatility & risk, SHPH or MTEX?

Do institutionals & insiders hold more shares of SHPH or MTEX?

Is SHPH or MTEX more profitable?

Which has stronger valuation & earnings, SHPH or MTEX?

Do analysts rate SHPH or MTEX?

Summary

How does Shuttle Pharmaceuticals compare to BioCardia?

Is SHPH or BCDA more profitable?

Do analysts prefer SHPH or BCDA?

Do institutionals and insiders hold more shares of SHPH or BCDA?

Which has more risk & volatility, SHPH or BCDA?

Which has higher earnings & valuation, SHPH or BCDA?

Does the media favor SHPH or BCDA?

Summary

How does Shuttle Pharmaceuticals compare to Bon Natural Life?

Do institutionals & insiders believe in SHPH or BON?

Which has higher valuation and earnings, SHPH or BON?

Do analysts prefer SHPH or BON?

Is SHPH or BON more profitable?

Which has more volatility and risk, SHPH or BON?

Does the media prefer SHPH or BON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHPH vs. The Competition

Shuttle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools